European Society for Medical Oncology (ESMO)

The European Society for Medical Oncology (ESMO) is the leading professional organization for medical oncology. With more than 25,000 members representing oncology professionals from over 150 countries worldwide, ESMO was founded in 1975.

Antitumor Activity of PM01183 in BRCA-Associated Metastatic Breast Cancer

PM01183 (lurbinectedin) is an investigational compound that blocks transactivated transcription and induces the formation of double-strand breaks in a range of cancer lines. This study is designed to evaluate whether the presence of BRCA1/2 mutations can act as a prognostic indicator of response to PM01183 in patients with metastatic breast cancer. Read More ›

First-Line Everolimus plus Letrozole in ER+/HER– Breast Cancer

The objective of this study is to evaluate the efficacy and safety of everolimus (an inhibitor of mammalian target of rapamycin) in combination with letrozole (an aromatase inhibitor) in postmenopausal women with advanced estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2–) breast cancer. Read More ›

Preoperative Metabolic Profiles Are Prognostic for Breast Cancer Recurrence

Patient-Reported Health Status Is Improved by the Addition of Palbociclib to Fulvestrant Treatment

Using the EQ-5D Health Index during the course of treatment, this study compares patient-reported general health status during treatment with palbociclib (a cyclin-dependent kinase 4/6 inhibitor) plus fulvestrant (a complete estrogen receptor antagonist) compared with during treatment with fulvestrant alone. Read More ›

Fulvestrant 500 mg Is Well-Tolerated and Efficacious in Women with Locally Advanced Breast Cancer

Fulvestrant (a complete estrogen receptor [ER] antagonist) represents an endocrine therapy for patients with ER-positive metastatic breast cancer who have disease progression after treatment with an antiestrogen. This study evaluates the clinical benefit rate of fulvestrant 500 mg monthly, defined as complete response, partial response, or stable disease lasting >24 weeks, in women with locally advanced breast cancer. Read More ›

Preliminary Safety and Efficacy of TAK-228 plus Exemestane or Fulvestrant in ER+/HER2– Metastatic Breast Cancer

TAK-228 is an investigational, oral, highly selective, ATP-competitive inhibitor of TORC1/2. By mitigating feedback within the PI3K/AKT/mTOR pathway, TAK-228 may restore sensitivity to endocrine therapies in patients who have progressed on such agents in combination with everolimus. This phase 1b/2 study evaluates the safety, pharmacokinetics, and preliminary efficacy of TAK-228 in combination with exemestane or fulvestrant. Read More ›

Circulating Tumor Cell Counts May Have Prognostic Value in Determining First-Line Therapy in HR+/HER2– Metastatic Breast Cancer

In patients with hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2–) metastatic breast cancer, the decision to treat first with hormone therapy or chemotherapy can be made at the discretion of the attending oncologist, or by taking into account the number of circulating tumor cells. This phase 3 study compares the outcome of these 2 methods. Read More ›

Claim Data Reveal Treatment and Toxicity Patterns Associated with Everolimus Use

Everolimus, an inhibitor of mammalian target of rapamycin, is approved for use in the United States and European Union in combination with exemestane (an aromatase inhibitor) for the treatment of postmenopausal women with advanced estrogen receptor–positive/human epidermal growth factor receptor 2–negative breast cancer. This retrospective study evaluates the patterns of care and complications associated with this treatment over a 5-year period (2009-2014). Read More ›

Next-Generation Sequencing Reveals Molecular Subtypes Beyond Those Defined by Hormone Receptor Expression

Exploratory Biomarkers in MONARCH 1: A Phase 2 Study of Abemaciclib Monotherapy in HR+/HER2– Metastatic Breast Cancer

Page 10 of 13

7
8
9
10
11
12
13